status of antioxidant defences in glucose-6-phosphate dehydrogenase deficient patients. The role of antioxidants to ameliorate hemolytic crisis

In human, G6PD deficiency is the most common enzymopathy affecting over 400 million people throughout the world. It is associated with higher potential for oxidative damage due to chronic redox imbalance in red cells that often results in clinical manifcstation of mild to severe hemolysis. The NADPH product of G6PD is required for the reductive biosynthetic reactions as well as for the stability of catalase, and the preservation of the reduced form of glutathione [GSH]. The aim of this study was to clarify the role of G6PD in cellular antioxidant defense; the level of glutathione, catalase, NADPH and estimate the level of malondialdehyde which reflect the oxidative stress across the cell membrane. Also to study the effect of antioxidant treatment [vitamins C and E] to ameliorate high sensitivity of red cells to oxidative stress. This study was carried out on fifty G6PD-deficient children during the attack. The children were classified into two groups: Group 1: received blood transfusion only, and considered as an antioxidant-untreated group. Group 2: Received blood transfusion as group I in addition to antioxidant therapy [antioxidant-treated group], and healthy control subjects as control group, Our study proved that hemolytic attack in G6PD deficient patients is due to a concomitant impairment of the two main mechanisms of detoxification of H[2]O[2] in RBCs; GSH system and catalase. The most important finding in this study is the efficiency of treatment with a combination of vitamin E and vitamin C may improve antioxidant status in G6PD deficient patients and in reducing the symptoms of hemolytic crises

Serum insulin-like growth factor 1 [IGF-1] and its binding protein 3 [IGFBP3] in relation to estrogen in postmenopausal patients with breast cancer receiving tamoxifen with and without vitamin A

This study included 30 postmenopausal women with breast cancer stages II and III. They were divided into two groups according to the line of adjuvant treatment [tamoxifen, oral tables of 10 mg twice daily or tamoxifen with vitamin A, oral tables 200 mg daily of vitamin A] as well as 15 normal healthy postmenopausal women matched in age with the patients group. The study aimed to investigate the effect of an antioxidant [vitamin A] besides tamoxifen as an adjuvant treatment in postmenopausal females with breast cancer as a reflection of change on the serum levels of IGF-I, its binding protein 3 [IGFBP3] and estrogen which were determined by immunoradiometric assay [IRMA] and radioimmunoassay [RIA]. After six months of adjuvant treatment with tamoxifen or tamoxifen with vitamin A, a statistically significant decrease in serum IGF-I and estrogen and a statistically significant increase in serum IGFBP3 level were observed